Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.
New data from the accounting platform Xero should give American entrepreneurs one more reason to be optimistic about 2025.
International Business Machines Corp. gave a stronger-than-expected revenue growth outlook for the coming years led by the ...
Fast-food restaurant owner Yum Brands is expecting stronger sales growth this year after it moves past challenges in its Middle East markets.
Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...
Chipotle Mexican Grill said on Tuesday that if President Donald Trump's proposed tariffs on Mexico go into full effect, the ...
Yum! Brands Inc. sales surpassed expectations, powered by growth at Taco Bell as the fast-food chain continues to sidestep a slowdown that has plagued many competitors.
Chipotle reduced its financial outlook for same-store sales this year to an increase in the low to mid-single digits.
Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.
Shares of Qualcomm Inc., the world’s biggest seller of smartphone processors, fell on investor fears that demand for new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback